In-depth trading ideas

Discover detailed market analysis from traders. See how others approach this instrument, compare different strategies, and discover perspectives that can shape your own view.

GTBP primed for a moonshot?Is NASDAQ:GTBP primed for a parabolic pump? The monthly chart is disastrous, but if you drill all the way down to the 4H chart, it looks to be coiling up. There are plenty of red flags with this name. Hemorrhaging funds and a lack of options are both warning signs. Technicals suggest there could be some type of turnaround brewing. If you've got money you could comfortably part with, maybe pick up a few shares on a long shot.

by quickshiftinn

potential to reach 11$ per share from the 0.70 its at So I asked a.i how this company was so undervalued and had it break down its analysis based off its competitors, what it offers and if its unqiue and if its possible for its value to raise, it IPO'd 2021 but it was established in the 1960s (could be wrong but it was the 1900's) now based off my conversation with it, this is the conclusion it drew. Based on our conversation, here is a summary of the key points regarding GT Biopharma's TriKE platform: * Unique Monotherapy: The TriKE platform i

by TheBlackBusinessMan

$GTBP MASSIVE MOVES Potentially HUGE earnings for my fellow day traders out there, it would seem NASDAQ:GTBP has pretty massive moves toward the upside and downside close to earnings dates, we're talking a 10$ move, putting a SL for under 2$ a share and a TP to its most recent 52W high or setting an alert could be a huge gain if your day trading and looking to lock in some consistent profit.

by TheBlackBusinessMan

Roadmap for GTBP If GTBP advances, it will enter a fast moving area as shown on the chart between downtrend lines. Previous trend gaps and fast moving prices areas are shown in the rectangles. Will likely need a catalyst. Blue solid lines are established downtrends, green dotted lines are established uptrends. Both the uptrend and downtrend lines are established from equilibrium points, (not highs and lows). Thickness of lines illustrates strength of previous price action. Circles are the crossing of uptrend an

by CrossfireTA

$GTBP A Breakthrough In Immuno Oncology The field of immuno-oncology has seen unprecedented growth in the past 10 years, that said GT Biopharma, Inc. (NASDAQ: GTBP) could potentially catapult the advancement of the field of immuno-oncology to a new order of magnitude. GTBP’s TriKEs tech is easier to administer, store, and produce than traditional CAR-T therapy. Additionally, it demonstrates extremely positive preclinical results. Currently, GTBP is set to submit INDs for two of its TriKEs treatments GTB-3650 and GTB-5550 in the second

by Penny_Stocks_Today

short term +3,500%GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform.

by UnknownUnicorn4521511

$GTBP Target PTs 30-35-40 and higher Pivoting off Support and up-trending towards Resistance GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. The company develops various immuno-oncology product candidates, including GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical tria

by UnknownUnicorn19246015

GTBP - DAILY GTBP - DAILY

by inspiredCharts